← Back to Search

NMDA receptor antagonist

Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease

Phase 3
Waitlist Available
Led By Erin L Furr Stimming, MD
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights
Pivotal Trial

Summary

This trial is testing a new drug to see if it helps with irritability in Huntington's disease patients.

Eligible Conditions
  • Huntington's Disease
  • Irritability

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Irritability as Assessed by The Irritability Scale
Irritability as Assessed by The Irritability Scale.
Secondary study objectives
Behavioral Symptoms, as Assessed by the Hospital Anxiety and Depression Scale (HADS).
Behavioral Symptoms, as Assessed by the Neuropsychiatric Inventory-Questionnaire (NPI-Q) - Caregiver Distress.
Behavioral Symptoms, as Assessed by the Neuropsychiatric Inventory-Questionnaire (NPI-Q) - Severity Score.
+12 more

Side effects data

From 2022 Phase 3 trial • 20 Patients • NCT03854019
10%
Headaches
5%
Primary care physician (PCP) prescribed medication for high blood pressure
5%
Insomnia
5%
Nausea
5%
Loss weight/decreased appetite
5%
Dizziness
5%
Increased libido
5%
Increased apathy
5%
COVID-19
100%
80%
60%
40%
20%
0%
Study treatment Arm
Dextromethorphan/Quinidine 20mg/10mg (DM/Q 20mg/10mg)
Placebo

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg), then PlaceboExperimental Treatment2 Interventions
Dextromethorphan/quinidine (DM/Q) 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.
Group II: Placebo, then Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)Placebo Group2 Interventions
Placebo one capsule once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)
2019
Completed Phase 3
~20
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

Cures Within ReachOTHER
23 Previous Clinical Trials
2,139 Total Patients Enrolled
The University of Texas Health Science Center, HoustonLead Sponsor
957 Previous Clinical Trials
348,074 Total Patients Enrolled
Erin L Furr Stimming, MDPrincipal InvestigatorThe University of Texas Health Science Center, Houston
~3 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top